Advanced search
News (114)
Companies (7)
Ubiquoss Inc. is a Korea-based company principally engaged in the manufacturing and distribution of network equipment. The Companyâs products portfolio includes ethernet switches; fiber-to-the-home (FTTH) equipment including gigabit passive optical netw ...
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brainâs ability to engage physiologic compensatory mechanisms enhancin ...
Eoptolink Technology Inc., Ltd. is a China-based company principally engaged in the research and development, manufacture and sale of optical modules. The Company's main products include point-to-point optical modules and passive optical network (PON) opt ...
Lightron Fiber-Optic Devices Inc, formerly LIGHTRON INC, is a Korea-based company engaged in the provision of optical module solutions for communications. The Company is engaged in the provision of passive optical network (PON) units, PON optical line ter ...
SOLiD, Inc. is a Korea-based company engaged in the manufacture of communication equipment such as wideband code division multiple access (WCDMA) repeaters and long term evolution (LTE) equipment. The Company mainly produces mobile communications equipmen ...
OE Solutions Co., Ltd. is a Korea-based company mainly engaged in the manufacture and distribution of optical transceivers. The Company mainly provides optical transceiver solutions for broadband wireless and wireline markets, including wireless backhaul, ...
Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brainâs ability to engage physiologic compensatory mechanisms enhancin ...
Insiders
Jaume Pons is the founder of ALX Oncology Ltd.
(founded in 2015) where he holds the title of President, Chief Executive Officer & Director.
He is also the founder of ALX Oncology Holdings, Inc. (founded in 2015) where he holds the title of President, Director & Chief Scientific Officer.
Currently, Dr. Pons is the President & Chief Executive Officer of ALX Oncology, Inc. He is also a Director at Tallac Therapeutics, Inc., Alexo Therapeutics International, Sirpant Therapeutics, and a Venture Partner at venBio Partners LLC.
Additionally, he serves as a Scientific Advisor at LSV Capital Management LLC.
In the past, Dr. Pons worked as the Chief Scientific Officer at Pfizer Inc. from 2007 to 2015.
He also held the position of Chief Scientific Officer at Rinat Neuroscience Corp.
from 2007 to 2015.
Dr. Pons completed his graduate degree at the University of California, Berkeley.
He also holds undergraduate, graduate, and doctorate degrees from Universitat Autònoma de Barcelona.
Jaume Perdigó Pons is currently an Investment Director at Miura Partners SGEIC SA since 2022.
He is also a Board Member at Citrico Global SL and TIERRA - Ingeniería y Paisajismo SL.
In the past, he worked as an Investment Analyst at Suma Capital SGEIC SA from 2016 to 2017 and as an Investment Banking Analyst at Greenhill & Co. Spain Ltd.
from 2017 to 2019.
Mr. Perdigó Pons completed his undergraduate degree at ESADE Business School in 2016.
No results for this search
- Stock Market
- Advanced search
- Jaume Pons
